Female Patients with Small Cell Lung Cancer Have Better Survival than Males with Extensive but Not Limited Disease.

IF 2 4区医学 Q3 ONCOLOGY

Oncology Research and Treatment Pub Date : 2024-01-01 Epub Date: 2024-07-22 DOI:10.1159/000540244

Faruk Tas, Akin Ozturk, Kayhan Erturk

{"title":"Female Patients with Small Cell Lung Cancer Have Better Survival than Males with Extensive but Not Limited Disease.","authors":"Faruk Tas, Akin Ozturk, Kayhan Erturk","doi":"10.1159/000540244","DOIUrl":null,"url":null,"abstract":"Introduction: Several previous studies have explored whether sex has prognostic significance in patients with small cell lung cancer (SCLC). In this retrospective study, we aimed to show the clinical significance of sex in SCLC patients.Methods: A total of 378 SCLC patients were assessed retrospectively.Results: Sixty-one (16.1%) patients were women; 26 of 131 (19.9%) patients had limited disease (LD-SCLC); and 14.2% of patients (35 of 247 patients) had extended disease (ED-SCLC). In all SCLC patients, regardless of stage, female patients were more likely to be nonsmokers (7.7 vs. 1%, p = 0.04 for LD-SCLC; and 11.4 vs. 1.4%, p = 0.001 for ED-SCLC) and more often to be anemic (26.9 vs. 11.4%, p = 0.04 for LD-SCLC; and 45.7 vs. 28%, p = 0.03 for ED-SCLC). While women with LD-SCLC were diagnosed younger (<60) than men (65.4 vs. 37.1%, p = 0.009), they had larger (>5 cm) tumors (69.2 vs. 42.9%, p = 0.01). Moreover, obesity (77.1 vs. 56.4%, p = 0.02) and less weight loss (88.6 vs. 73.6%, p = 0.04) were more common in women with ED-SCLC than in men. However, there were no associations between sex and significant prognostic factors, such as performance status, metastasis site, serum LDH level, response to chemotherapy, and disease recurrence. Outcomes in LD-SCLC patients were found to be similar between sexes; median overall survivals in women compared to men was 18 versus 15 months, respectively (p = 0.8). On the other hand, female patients with ED-SCLC had better survivals; median survivals for women versus men were 10 versus 7 months, respectively (p = 0.008). This significance for female ED-SCLC patients was also maintained in the multivariate analysis (p = 0.001).Conclusion: While the survival rates of female patients, who constitute a small proportion of SCLC patients, are no different from men in LD-SCLC, they are better in ED-SCLC.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"401-409"},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540244","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Several previous studies have explored whether sex has prognostic significance in patients with small cell lung cancer (SCLC). In this retrospective study, we aimed to show the clinical significance of sex in SCLC patients.

Methods: A total of 378 SCLC patients were assessed retrospectively.

Results: Sixty-one (16.1%) patients were women; 26 of 131 (19.9%) patients had limited disease (LD-SCLC); and 14.2% of patients (35 of 247 patients) had extended disease (ED-SCLC). In all SCLC patients, regardless of stage, female patients were more likely to be nonsmokers (7.7 vs. 1%, p = 0.04 for LD-SCLC; and 11.4 vs. 1.4%, p = 0.001 for ED-SCLC) and more often to be anemic (26.9 vs. 11.4%, p = 0.04 for LD-SCLC; and 45.7 vs. 28%, p = 0.03 for ED-SCLC). While women with LD-SCLC were diagnosed younger (<60) than men (65.4 vs. 37.1%, p = 0.009), they had larger (>5 cm) tumors (69.2 vs. 42.9%, p = 0.01). Moreover, obesity (77.1 vs. 56.4%, p = 0.02) and less weight loss (88.6 vs. 73.6%, p = 0.04) were more common in women with ED-SCLC than in men. However, there were no associations between sex and significant prognostic factors, such as performance status, metastasis site, serum LDH level, response to chemotherapy, and disease recurrence. Outcomes in LD-SCLC patients were found to be similar between sexes; median overall survivals in women compared to men was 18 versus 15 months, respectively (p = 0.8). On the other hand, female patients with ED-SCLC had better survivals; median survivals for women versus men were 10 versus 7 months, respectively (p = 0.008). This significance for female ED-SCLC patients was also maintained in the multivariate analysis (p = 0.001).

Conclusion: While the survival rates of female patients, who constitute a small proportion of SCLC patients, are no different from men in LD-SCLC, they are better in ED-SCLC.

查看原文本刊更多论文

女性小细胞肺癌患者的生存率要高于病情广泛但不局限的男性患者。

导言之前有几项研究探讨了性别对小细胞肺癌（SCLC）患者的预后是否有意义。在这项回顾性研究中，我们旨在显示性别在小细胞肺癌患者中的临床意义：方法：我们对 378 名 SCLC 患者进行了回顾性评估：结果：61 名（16.1%）患者为女性；131 名患者中有 26 名（19.9%）为局限性疾病（LD-SCLC）；14.2% 的患者（247 名患者中有 35 名）为扩展性疾病（ED-SCLC）。在所有SCLC患者中，无论处于哪个阶段，女性患者都更有可能不吸烟（LD-SCLC为7.7%对1%，P=0.04；ED-SCLC为11.4%对1.4%，P=0.001），而且更容易贫血（LD-SCLC为26.9%对11.4%，P=0.04；ED-SCLC为45.7%对28%，P=0.03）。虽然女性 LD-SCLC 患者的确诊年龄（60 岁）小于男性（65.4% 对 37.1%，P=0.009），但她们的肿瘤更大（5 厘米）（69.2% 对 42.9%，P=0.01）。此外，肥胖（77.1% 对 56.4%，P=0.02）和体重减轻（88.6% 对 73.6%，P=0.04）在女性 ED-SCLC 患者中比男性更常见。然而，性别与重要的预后因素（如表现状态、转移部位、血清 LDH 水平、化疗反应和疾病复发）之间没有关联。研究发现，LD-SCLC 患者的预后在性别上相似；女性和男性的中位总生存期分别为 18 个月和 15 个月（P=0.8）。另一方面，ED-SCLC女性患者的存活期较长；女性与男性的中位存活期分别为10个月和7个月（P=0.008）。在多变量分析中，ED-SCLC 女性患者的这一显著性也得以保持（P=0.001）：结论：女性患者只占 SCLC 患者的一小部分，在 LD-SCLC 中，女性患者的存活率与男性无异，但在 ED-SCLC 中，女性患者的存活率更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Research and Treatment ONCOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.